Coherence principles in dose-finding studies

DOI10.1093/BIOMET/92.4.863MaRDI QIDQ3545408zbMATH OpenOpenAlexFDO

Authors Ying Kuen Cheung

Publication date 10 December 2008

Published in Biometrika (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1093/biomet/92.4.863

zbMATH Keywords

compatibilitygrouped accrualphase I trialtwo-stage design

Mathematics Subject Classification ID

Estimation in survival analysis and censored data (62N02) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Recommendations

• Cumulative cohort design for dose-finding
• Design efficiency in dose finding studies
• Optimal designs for dose-finding studies
• Efficiency of bridging between related dose finding studies
• Performance Measures in Dose‐Finding Experiments
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• A Note on Multiple Testing Procedures in Dose Finding

Cited in

(25)

• Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
• Optimal designs for dose-escalation trials and individual allocations in cohorts
• Adaptive clinical trial designs for phase I cancer studies
• Cumulative cohort design for dose-finding
• Continual reassessment method for partial ordering
• Incorporating individual and collective ethics into phase I cancer trial designs
• scientific article; zbMATH DE number 4176221 (Why is no real title available?)
• Continual reassessment method with multiple toxicity constraints
• Efficiency of bridging between related dose finding studies
• Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations
• Biometric practicesimple benchmark for complex dose finding studies
• Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
• Posterior Predictive Design for Phase I Clinical Trials
• A product of independent beta probabilities dose escalation design for dual-agent phase I trials
• Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials
• Dimension of model parameter space and operating characteristics in adaptive dose-finding studies
• Adaptive prior variance calibration in the Bayesian continual reassessment method
• Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
• Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
• Stochastic approximation and modern model-based designs for dose-finding clinical trials
• Continual reassessment and related dose-finding designs
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• Bayesian models and decision algorithms for complex early phase clinical trials
• Approximate dynamic programming and its applications to the design of Phase I cancer trials
• Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach

This page was built for publication: Coherence principles in dose-finding studies

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3545408)